This month's Editor's favorite is Clinical, Dopaminergic, and Metabolic Correlations in Parkinson Disease A Dual-Tracer PET Study​ by Liu FT, et al. In a cross-sectional, retrospective analysis, authors compared dopaminergic binding (11C-CFT) and glucose metabolism (18F-FDG) in 103 participants with Parkinson disease. Striatal DAT binding correlated with akinesia-rigidity (P < 0.001) but not with tremor. Metabolic PET disclosed a set of brain regions correlating with the cardinal symptoms, including tremor. Unilateral symptoms correlated with the contralateral nigrostriatal dopamine loss, but with bilateral metabolic changes. Image-to-image comparison revealed that dopaminergic dysfunction correlated with widely distributed metabolic changes in Parkinson disease, and there was moderate imaging-to-clinical correlation.​

Current Issue

Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures

Willegaignon, José; Crema, Karin Paola; Oliveira, Nathaliê Canhameiro; More

Clinical Nuclear Medicine. 43(8):572-578, August 2018.

Assessment of Treatment Response by 99mTc-MIP-1404 SPECT/CT: A Pilot Study in Patients With Metastatic Prostate Cancer

Schmidkonz, Christian; Cordes, Michael; Beck, Michael; More

Clinical Nuclear Medicine. 43(8):e250-e258, August 2018.

Brain Metastasis of Medullary Thyroid Carcinoma Without Macroscopic Calcification Detected First on 68Ga-Dotatate and Then on 18F-Fluoride PET/CT

Duarte, Paulo Schiavom; Marin, José Flávio Gomes; De Carvalho, José Willegaignon De Amorim; More

Clinical Nuclear Medicine. 43(8):623-624, August 2018.